Use of Recombinant Factor VII as a Prophylactic Therapy for Adolescent Females With Heavy Menstrual Bleeding
Completed
- Conditions
- Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention
- Interventions
- Drug: Proph7
- Registration Number
- NCT06258980
- Lead Sponsor
- Minia University Hospital
- Brief Summary
the study is conducted on adolescent females proved to be Glanzmanns Thrombaesthenia with heavy menstrual bleeding by the use of 3 doses of recombinant factor VII in the first day of their cycles. bleeding profile and quality of life were assessed before and 1year after this regular recombinant factor VII administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 3
Inclusion Criteria
- adolescent females proved to be Glanzmanns Thrombaesthenia heavy menstrual bleeding no improvment by platelet transfusion or antifibrinolytic therapy
Exclusion Criteria
chronic systemic disease previous allergic reaction to recombinant FVII
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description heavily menstruating females with glanzmannns Thrombaesthenia Proph7 -
- Primary Outcome Measures
Name Time Method regular accepted menstrual cycles less than 6 days 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Gehan Lotfy Abdel Hakeem
🇪🇬Al Minyā, Egypt